Thyrocare Technologies Limited announced its audited financial results for the quarter and financial year ended March 31, 2026, reporting a consolidated total income of Rs. 228.26 Crores for the fourth quarter. The company’s revenue from operations for Q4 FY26 stood at Rs. 223.95 Crores, representing a 14.53% increase from the previous quarter’s Rs. 195.53 Crores and a 19.66% growth compared to Rs. 187.16 Crores in the same quarter last year. The consolidated net profit for the quarter reached Rs. 34.69 Crores, reflecting a significant 40.56% growth from the previous quarter’s Rs. 24.68 Crores and a 42.64% increase from Rs. 24.32 Crores reported in the corresponding quarter of the previous year. Alongside these results, the Board recommended a final dividend of Rs. 7.00 per equity share for the financial year 2025-26.

Thyrocare Technologies Limited is a leading Indian diagnostics company specializing in high-volume, affordable testing services with a focus on thyroid and routine pathology. The company operates a sophisticated network of clinical laboratories and collection centers, utilizing automated platforms to provide reliable healthcare diagnostics. In recent strategic moves, the Board approved a further investment of up to Rs. 5.50 Crores in its wholly-owned subsidiary, Think Health Diagnostics Private Limited, to bolster its diagnostic platform. Additionally, the company is broadening its operational scope by altering its Memorandum of Association to include allied healthcare activities, point-of-care devices, and digital health platforms. As of early 2026, the company continues its leadership under the re-appointed Chairman and Managing Director, Mr. Rahul Franklin Guha.